|
1
|
Karagiannis GS, Poutahidis T, Erdman SE,
Kirsch R, Riddell RH and Diamandis EP: Cancer-associated
fibroblasts drive the progression of metastasis through both
paracrine and mechanical pressure on cancer tissue. Mol Cancer Res.
10:1403–1418. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lorusso G and Rüegg C: The tumor
microenvironment and its contribution to tumor evolution toward
metastasis. Histochem Cell Biol. 130:1091–1103. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Joyce JA and Pollard JW:
Microenvironmental regulation of metastasis. Nat Rev Cancer.
9:239–252. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Franco OE, Shaw AK, Strand DW and Hayward
SW: Cancer associated fibroblasts in cancer pathogenesis. Semin
Cell Dev Biol. 21:33–39. 2010. View Article : Google Scholar :
|
|
5
|
Kalluri R and Zeisberg M: Fibroblasts in
cancer. Nat Rev Cancer. 6:392–401. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sanz-Moreno V, Gaggioli C, Yeo M,
Albrengues J, Wallberg F, Viros A, Hooper S, Mitter R, Féral CC,
Cook M, et al: ROCK and JAK1 signaling cooperate to control
actomyosin contractility in tumor cells and stroma. Cancer Cell.
20:229–245. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Gaggioli C, Hooper S, Hidalgo-Carcedo C,
Grosse R, Marshall JF, Harrington K and Sahai E: Fibroblast-led
collective invasion of carcinoma cells with differing roles for
RhoGTPases in leading and following cells. Nat Cell Biol.
9:1392–1400. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chan CJ, Smyth MJ and Martinet L:
Molecular mechanisms of natural killer cell activation in response
to cellular stress. Cell Death Differ. 21:5–14. 2014. View Article : Google Scholar
|
|
9
|
Calon A, Tauriello DV and Batlle E:
TGF-beta in CAF-mediated tumor growth and metastasis. Semin Cancer
Biol. 25:15–22. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Salaroglio IC, Campia I, Kopecka J,
Gazzano E, Orecchia S, Ghigo D and Riganti C: Zoledronic acid
overcomes chemoresistance and immunosuppression of malignant
mesothelioma. Oncotarget. 6:1128–1142. 2015. View Article : Google Scholar :
|
|
11
|
Tahara-Hanaoka S, Shibuya K, Onoda Y,
Zhang H, Yamazaki S, Miyamoto A, Honda S, Lanier LL and Shibuya A:
Functional characterization of DNAM-1 (CD226) interaction with its
ligands PVR (CD155) and nectin-2 (PRR-2/CD112). Int Immunol.
16:533–538. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bottino C, Castriconi R, Pende D, Rivera
P, Nanni M, Carnemolla B, Cantoni C, Grassi J, Marcenaro S, Reymond
N, et al: Identification of PVR (CD155) and Nectin-2 (CD112) as
cell surface ligands for the human DNAM-1 (CD226) activating
molecule. J Exp Med. 198:557–567. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Atsumi S, Matsumine A, Toyoda H, Niimi R,
Iino T and Sudo A: Prognostic significance of CD155 mRNA expression
in soft tissue sarcomas. Oncol Lett. 5:1771–1776. 2013.PubMed/NCBI
|
|
14
|
Tanizaki Y, Kobayashi A, Toujima S, Shiro
M, Mizoguchi M, Mabuchi Y, Yagi S, Minami S, Takikawa O and Ino K:
Indoleamine 2,3-dioxygenase promotes peritoneal metastasis of
ovarian cancer by inducing an immunosuppressive environment. Cancer
Sci. 105:966–973. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kasatori N, Ishikawa F, Ueyama M and
Urayama T: A differential assay of NK-cell-mediated cytotoxicity in
K562 cells revealing three sequential membrane impairment steps
using three-color flow-cytometry. J Immunol Methods. 307:41–53.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yoshida N, Ino K, Ishida Y, Kajiyama H,
Yamamoto E, Shibata K, Terauchi M, Nawa A, Akimoto H, Takikawa O,
et al: Overexpression of indoleamine 2,3-dioxygenase in human
endometrial carcinoma cells induces rapid tumor growth in a mouse
xenograft model. Clin Cancer Res. 14:7251–7259. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Löb S, Königsrainer A, Rammensee HG, Opelz
G and Terness P: Inhibitors of indoleamine-2,3-dioxygenase for
cancer therapy: Can we see the wood for the trees? Nat Rev Cancer.
9:445–452. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
18
|
Pegram HJ, Andrews DM, Smyth MJ, Darcy PK
and Kershaw MH: Activating and inhibitory receptors of natural
killer cells. Immunol Cell Biol. 89:216–224. 2011. View Article : Google Scholar
|
|
19
|
Augsten M: Cancer-associated fibroblasts
as another polarized cell type of the tumor microenvironment. Front
Oncol. 4:622014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yan X, Luo H, Zhou X, Zhu B, Wang Y and
Bian X: Identification of CD90 as a marker for lung cancer stem
cells in A549 and H446 cell lines. Oncol Rep. 30:2733–2740.
2013.PubMed/NCBI
|
|
21
|
True LD, Zhang H, Ye M, Huang CY, Nelson
PS, von Haller PD, Tjoelker LW, Kim JS, Qian WJ, Smith RD, et al:
CD90/THY1 is overexpressed in prostate cancer-associated
fibroblasts and could serve as a cancer biomarker. Mod Pathol.
23:1346–1356. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lu H, Clauser KR, Tam WL, Fröse J, Ye X,
Eaton EN, Reinhardt F, Donnenberg VS, Bhargava R, Carr SA, et al: A
breast cancer stem cell niche supported by juxtacrine signalling
from monocytes and macrophages. Nat Cell Biol. 16:1105–1117. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Alter G, Malenfant JM and Altfeld M:
CD107a as a functional marker for the identification of natural
killer cell activity. J Immunol Methods. 294:15–22. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Qu P, Huang X, Zhou X, Lü Z, Liu F, Shi Z,
Lü L, Wu Y and Chen Y: Loss of CD155 expression predicts poor
prognosis in hepatocellular carcinoma. Histopathology. 66:706–714.
2015. View Article : Google Scholar
|
|
25
|
Gong J, Fang L, Liu R, Wang Y, Xing J,
Chen Y, Zhuang R, Zhang Y, Zhang C, Yang A, et al: UPR decreases
CD226 ligand CD155 expression and sensitivity to NK cell-mediated
cytotoxicity in hepatoma cells. Eur J Immunol. 44:3758–3767. 2014.
View Article : Google Scholar : PubMed/NCBI
|
